| Hazard Information | Back Directory | [Uses]
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer[1][2]. | [in vivo]
Vesencumab (10 mg/kg, ip, twice a week for 7 weeks) exhibits antitumor effect in mouse SUM159 orthotopic xenograft models[3]. | Animal Model: | Mouse SUM159 orthotopic xenograft models[3] | | Dosage: | 10 mg/kg | | Administration: | ip, twice a week for 7 weeks | | Result: | Inhibited tumor volume and weight. |
| [References]
[1] Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
[2] Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362. DOI:10.3390/cells11213362 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|